Aviado · Research
Longevity Daily
Friday, May 1, 2026
Listen
Today's Brief
A breakthrough on Alzheimer's neuroinflammation leads today: researchers identified the molecular switch that drives brain immune cell inflammation and — when blocked in mice — preserves the synapses critical for memory and thinking. Aviado's new niacin analysis reveals a powerful but double-edged supplement: it's the only OTC compound that can slash Lp(a) by 37%, yet the same dose worsens insulin resistance by up to 88%. New findings complicate the high-altitude longevity narrative, the FDA's expected peptide policy reversal will reshape legal access for health optimizers, and a surprising study shows rapamycin may blunt the benefits of exercise.
10 stories5 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
Researchers Pinpoint the Molecular Switch That Fuels Alzheimer's Neuroinflammation
Scientists identified S-nitrosylation — a specific chemical modification of the STING protein at cysteine 148 — as the key step that activates chronic immune cell inflammation in Alzheimer's disease. In mouse models, blocking this modification significantly reduced neuroinflammation and, critically, preserved synapses — the nerve connections essential for memory and thinking that are progressively lost in dementia. Loss of synapses is one of the strongest predictors of cognitive decline, making this a particularly compelling mechanistic target. This remains early-stage animal research, but it offers a precise entry point for therapies that could reduce Alzheimer's inflammation without broadly suppressing immune function.
Read more →Supplements & Compounds
Niacin Raises HDL and Lowers Lp(a) — But Also Worsens Insulin Resistance: How to Know If the Trade-Off Works for You
Niacin is the only over-the-counter supplement that can cut Lp(a) by up to 37% while raising HDL by 16% — but the effective dose of 1,500–2,000 mg/day also worsens insulin resistance by 42–88%, raising fasting glucose in a meaningful fraction of users. Whether this trade-off makes sense depends on your individual biomarkers: high Lp(a) with normal glucose is a green light; already-elevated fasting glucose or HOMA-IR is a red flag. Aviado walks through the exact testing protocol and dosing ramp to help you make a data-driven decision.
Read the full Aviado analysis →Probiotics and Postbiotics Improve Stress, Gut Balance, and Vitality in People with Sub-Clinical Anxiety
A new ADM study found that people with sub-clinical anxiety showed measurable improvements in microbial diversity, vitality scores, and self-reported stress after taking a combination of probiotics and postbiotics. This adds concrete data to the gut-brain axis hypothesis — increasingly actionable for people managing low-grade stress without pharmaceutical intervention. Caveat: the study was conducted by ADM, a company with a direct commercial interest in the outcome, so independent replication would strengthen confidence in the findings.
Read more →Bovine Colostrum Is Trending — Here's What the Evidence Actually Supports
Bovine colostrum — rich in immunoglobulins, lactoferrin, and growth factors — is gaining traction across gut health, immunity, sports nutrition, and beauty categories, but the evidence base is uneven across applications. Nutritional Outlook's FAQ examines where the science is strongest, what quality considerations matter when sourcing it, and where marketing claims outpace the data. Worth reading before adding it to your stack.
Read more →Research & Papers
Young-Donor Fecal Transplants Suppress an Aging-Linked Gene and Reduce Liver Cancer Risk in Mice
Fecal microbiota transplantation (FMT) from young mice to old mice suppressed age-related increases in MDM2 — a protein linked to elevated liver cancer risk — and reduced tumor development in the recipients. This builds on a growing body of animal evidence that restoring a youthful gut microbiome can reverse disease-promoting changes that accumulate with age; FMT is one of the few interventions capable of making lasting changes to microbiome composition. Mouse study, but the specificity of the MDM2 mechanism gives researchers a concrete target to pursue in future human research.
Read more →Living at High Altitude Accelerates Immune Aging, Despite Cardiovascular Benefits at Moderate Elevation
New research finds that populations living at sustained high altitude show markers of accelerated immune aging — a counterintuitive finding given well-known cardiovascular benefits associated with moderate-altitude living. The key distinction appears to be dose: intermittent mild hypoxia (as in altitude training) may trigger beneficial adaptations, while chronic sustained mild hypoxia appears to stress the immune system in ways that promote premature aging. This is observational data requiring further mechanistic work, but it complicates the assumption that high-altitude living is uniformly beneficial for longevity.
Read more →Why Some Leading Longevity Researchers Are Betting on Replacement Over Repair
A new perspective in *Aging Cell* argues that repair-based aging interventions have fundamental ceilings, and that physically replacing damaged cells, organelles, and molecules may be necessary to achieve meaningful rejuvenation. The authors map a research roadmap integrating replacement strategies with next-generation damage-removal therapies designed to restore function system-wide. This is a conceptual framework rather than a clinical finding, but it reflects a genuine strategic shift in how leading longevity scientists are approaching the problem.
Read more →Lifestyle & Nutrition
Can You Delay Menopause to 60? Inside One Biohacker's Experimental Ovarian Aging Protocol
A Business Insider writer details her effort to push menopause from a predicted age 55 to 60 by targeting three hallmarks of ovarian aging: egg loss, mitochondrial dysfunction, and ovarian tissue stiffening. Her approach includes rapamycin — currently being studied in the VIBRANT clinical trial specifically for ovarian aging — alongside mitochondria-targeted interventions; her ovarian age currently tests at 30, five years below her chronological age. This is an n=1 self-experiment rather than a clinical recommendation, and the VIBRANT trial results will be far more informative, but it offers a useful window into the cutting edge of female longevity science.
Read more →Industry & Policy
FDA Expected to Lift Restrictions on Compounded Peptides, Heeding RFK Jr.'s Wishes
The FDA is poised to reverse its restrictions on compounded peptides — including compounds like BPC-157 and TB-500 commonly sourced by health optimizers from compounding pharmacies — which had been flagged for unproven anti-aging and disease-fighting claims. For people who use or have wanted to use these compounds, this signals easier legal access is coming; for now, regulatory status remains in flux. The NYT is careful to note that lifting restrictions is not an endorsement of safety or efficacy — the evidence base for most peptides remains limited, and users should calibrate expectations accordingly.
Read more →Rapamycin's Surprising Downside for Exercise — Plus TruDiagnostic Acquires David Sinclair's Tally Health
Two significant longevity industry developments: new research found rapamycin had a "surprisingly negative impact on exercise," challenging the assumption that stacking the mTOR inhibitor with active training is straightforwardly additive — a nuance that rapamycin users should track closely as more details emerge. Separately, Infinite Epigenetics (parent of TruDiagnostic) acquired Tally Health — co-founded by David Sinclair — in what's described as the largest acquisition in epigenetic age testing to date. Both stories reflect a longevity field simultaneously confronting inconvenient data and accelerating commercial consolidation.
Read more →